All Deals
May 6, 2025 - Deals
NewLimit Raises $130 Million In Series B Funding Led By Kleiner Perkins
NewLimit, a biotech startup co-founded by Coinbase CEO Brian Armstrong, Blake Byers, and stem cell expert Jacob Kimmel, has raised $130 million in a Series B round led by Kleiner Perkins to advance its mission of developing age-reversing treatments through epigenetic reprogramming. The round included new investors Nat Friedman, Daniel Gross, and Khosla Ventures, alongside returning backers like Founders Fund and Patrick Collison. The company, now over four years old, has identified three prototype drugs that rejuvenate liver cells and is leveraging AI to accelerate discovery in a “lab-in-a-loop” model, though human trials remain a few years away.
INVESTORS: Kleiner Perkins, Nat Friedman, Daniel Gross, Khosla Ventures, Founders Fund, Dimension Capital, Elad Gil, Garry Tan & Patrick Collison
ROUND: Series B
AMOUNT: $130,000,000
HQ: #SanFrancisco #California
#VentureCapital #NewLimit #BrianArmstrong #BlakeByers #JacobKimmel #KleinerPerkins #NatFriedman #DanielGross #KhoslaVentures #FoundersFund #DimensionCapital #EladGil #GarryTan #PatrickCollison #TradedVC
More Deals
View All
Colossal Biosciences In Talks For Funding Round Targeting $23 Billion ValuationColossal Biosciences, the de-extinction biotech startup known for its efforts to recreate the woolly mammoth and other extinct species, is reportedly in talks to raise new funding at a valuation of roughly $23 billion–$24 billion, according to Axios. The potential raise would mark a significant jump for the five-year-old company, with investors valuing not only its genetic-engineering programs but also its broader genomics, reproductive technology, conservation, and intellectual property platform. Colossal has begun generating revenue through conservation technology sales and technology spinouts, including Astromech, an AI-driven predictive modeling company, and Form Bio, a computational biology platform, expanding its value beyond de-extinction efforts.
FOUNDERS: Ben Lamm & George Church
TARGET VALUATION: $23,000,000,000
HQ: Dallas, Texas
#VentureCapital #ColossalBiosciences #BenLamm #GeorgeChurch #TradedVC